GreenLight Biosciences went public via a SPAC merger with Environmental Impact Acquisition in a $1.2bn deal.

GreenLight Biosciences, an integrated life sciences company, went public via a SPAC merger with Environmental Impact Acquisition in a $1.2bn deal. Investors in PIPE include 2G Ventures, Cormorant Asset Management, Morningside Venture Investments, Hudson Bay Capital, BNP Paribas, The Jeremy and Hannelore Grantham Environmental Trust, Continental Grain Company, Pura Vida Investments, Xeraya Capital, and MLS Fund II. “We believe that GreenLight’s breakthrough platform can create advanced therapies, vaccines, and crop-protection products that address—quickly, directly, and specifically—some of the most significant problems facing the world today. Going public through this partnership will accelerate development and commercialization by enabling us to attract the talent, purchase the tools, scale our manufacturing infrastructure, advance regulatory approvals, and develop further the science necessary to address some of humanity’s most pressing challenges," Andrey Zarur, GreenLight Co-Founder and CEO.